Bio-Rad Laboratories (FRA:BUWA) Beneish M-Score: -2.60 (As of Jun. 25, 2026)


FRA:BUWA Bio-Rad Laboratories Inc FRA:BUWA
72 GF Score
Price €246.00
GF Value €272.84
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Bio-Rad Laboratories Beneish M-Score?

Bio-Rad Laboratories FRA:BUWA +3.27% 72 Beneish M-Score is -2.60 as of Jun. 25, 2026. GuruFocus rates FRA:BUWA with a GF Score™ of 72/100 and a GF Value™ of €272.84 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 765 Medical Devices & Instruments companies, Bio-Rad Laboratories ranks better than 52.42% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.6 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Bio-Rad Laboratories's Beneish M-Score or its related term are showing as below:

FRA:BUWA' s Beneish M-Score Range Over the Past 10 Years
Min: -2.84   Med: -2.56   Max: -2.15
Current: -2.6

During the past 13 years, the highest Beneish M-Score of Bio-Rad Laboratories was -2.15. The lowest was -2.84. And the median was -2.56.


Bio-Rad Laboratories Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Bio-Rad Laboratories's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Rad Laboratories Beneish M-Score Chart

Bio-Rad Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.69 -2.53 -2.43 -2.52 -2.61

Bio-Rad Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.52 -2.58 -2.54 -2.61 -2.60

FRA:BUWA vs BRKR, MASI, PODD: Beneish M-Score Comparison

For the Medical Devices subindustry, Bio-Rad Laboratories's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Rad Laboratories Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's Beneish M-Score falls into.


FRA:BUWA
72GF Score
Bio-Rad Laboratories Inc FRA:BUWA
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio-Rad Laboratories Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Bio-Rad Laboratories for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9941+0.528 * 1.0305+0.404 * 1.0317+0.892 * 0.944+0.115 * 0.9397
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0301+4.679 * -0.030723-0.327 * 0.9863
=-2.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €369 Mil.
Revenue was 512.166 + 591.993 + 556.356 + 564.937 = €2,225 Mil.
Gross Profit was 267.631 + 294.801 + 292.577 + 299.375 = €1,154 Mil.
Total Current Assets was €2,545 Mil.
Total Assets was €8,468 Mil.
Property, Plant and Equipment(Net PPE) was €596 Mil.
Depreciation, Depletion and Amortization(DDA) was €145 Mil.
Selling, General, & Admin. Expense(SGA) was €729 Mil.
Total Current Liabilities was €793 Mil.
Long-Term Debt & Capital Lease Obligation was €814 Mil.
Net Income was -455.941 + 614.88 + -291.299 + 275.533 = €143 Mil.
Non Operating Income was -633.699 + 731.366 + -422.933 + 290.272 = €-35 Mil.
Cash Flow from Operations was 93.506 + 140.825 + 103.007 + 101.005 = €438 Mil.
Total Receivables was €393 Mil.
Revenue was 541.495 + 637.463 + 585.38 + 593.167 = €2,358 Mil.
Gross Profit was 283.05 + 326.515 + 320.666 + 329.888 = €1,260 Mil.
Total Current Assets was €2,809 Mil.
Total Assets was €8,812 Mil.
Property, Plant and Equipment(Net PPE) was €631 Mil.
Depreciation, Depletion and Amortization(DDA) was €142 Mil.
Selling, General, & Admin. Expense(SGA) was €749 Mil.
Total Current Liabilities was €469 Mil.
Long-Term Debt & Capital Lease Obligation was €1,227 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(368.663 / 2225.452) / (392.847 / 2357.505)
=0.165658 / 0.166637
=0.9941

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1260.119 / 2357.505) / (1154.384 / 2225.452)
=0.534514 / 0.518719
=1.0305

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2544.916 + 596.331) / 8468.35) / (1 - (2808.855 + 630.572) / 8812.382)
=0.62906 / 0.609705
=1.0317

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2225.452 / 2357.505
=0.944

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(141.543 / (141.543 + 630.572)) / (144.531 / (144.531 + 596.331))
=0.183319 / 0.195085
=0.9397

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(728.73 / 2225.452) / (749.396 / 2357.505)
=0.327453 / 0.317877
=1.0301

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((814.397 + 793.205) / 8468.35) / ((1227.475 + 468.605) / 8812.382)
=0.189837 / 0.192466
=0.9863

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(143.173 - -34.994 - 438.343) / 8468.35
=-0.030723

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Bio-Rad Laboratories has a M-score of -2.66 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.60 mean?
Bio-Rad Laboratories (FRA:BUWA) has a Beneish M-Score of -2.60 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Bio-Rad Laboratories and its competitors. According to the industry distribution chart, Bio-Rad Laboratories ranks #364 out of 765 companies in the Medical Devices & Instruments industry, placing it in the top 47.6%.
Is Bio-Rad Laboratories' Beneish M-Score too high?
Bio-Rad Laboratories' current Beneish M-Score is -2.60. Based on the distribution chart, Bio-Rad Laboratories ranks #364 out of 765 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bio-Rad Laboratories has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' Beneish M-Score compare to BRKR and MASI?
According to the Medical Devices & Instruments industry distribution chart, Bio-Rad Laboratories ranks #364 out of 765 companies for Beneish M-Score. This puts Bio-Rad Laboratories in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Bio-Rad Laboratories and its competitors. Bio-Rad Laboratories's current Beneish M-Score is -2.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Modestly Undervalued. The stock's GF Value™ is €272.84, compared to a current price of €246.00 — trading 9.8% below its estimated fair value. The current Beneish M-Score is -2.60. Bio-Rad Laboratories' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current Beneish M-Score is -2.60 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be undervalued. The current stock price of €246.00 is trading 9.8% below its estimated GF Value™ of €272.84. GuruFocus considers Bio-Rad Laboratories to be Modestly Undervalued.

Key valuation signals for FRA:BUWA:

  • Beneish M-Score: -2.60
  • GF Value™: €272.84 vs. price of €246.00 (9.8% below fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bio-Rad Laboratories Business Description

Address 1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
72GF Score

Get the complete analysis for FRA:BUWA

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€246.00
Price
€272.84
GF Value